Renasant Bank Boosts Stock Holdings in AbbVie Inc. $ABBV

Renasant Bank raised its stake in AbbVie Inc. (NYSE:ABBV) by 142.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,955 shares of the company’s stock after acquiring an additional 2,914 shares during the period. Renasant Bank’s holdings in AbbVie were worth $1,078,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ABBV. Aljian Capital Management LLC grew its position in shares of AbbVie by 15.0% during the first quarter. Aljian Capital Management LLC now owns 7,000 shares of the company’s stock valued at $1,522,000 after purchasing an additional 914 shares in the last quarter. Bank of Stockton lifted its position in shares of AbbVie by 1.8% in the first quarter. Bank of Stockton now owns 3,857 shares of the company’s stock worth $839,000 after buying an additional 69 shares in the last quarter. Evergreen Private Wealth LLC lifted its position in shares of AbbVie by 11.8% in the first quarter. Evergreen Private Wealth LLC now owns 1,055 shares of the company’s stock worth $229,000 after buying an additional 111 shares in the last quarter. Hoey Investments Inc. boosted its stake in AbbVie by 5.5% during the first quarter. Hoey Investments Inc. now owns 3,867 shares of the company’s stock valued at $841,000 after buying an additional 200 shares during the last quarter. Finally, Resonant Capital Advisors LLC grew its holdings in AbbVie by 9.6% during the 1st quarter. Resonant Capital Advisors LLC now owns 16,835 shares of the company’s stock valued at $3,661,000 after buying an additional 1,480 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of ABBV stock opened at $254.71 on Wednesday. The company has a market cap of $450.02 billion, a PE ratio of 125.47, a price-to-earnings-growth ratio of 0.84 and a beta of 0.30. AbbVie Inc. has a 1 year low of $184.63 and a 1 year high of $261.64. The stock’s 50 day simple moving average is $222.39 and its two-hundred day simple moving average is $220.69.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the previous year, the company posted $2.46 EPS. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. Equities research analysts expect that AbbVie Inc. will post 14.28 EPS for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s payout ratio is 340.89%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved TEPKINLY (epcoritamab) plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, making it the first and only bispecific-based therapy approved in Europe for this setting and expanding AbbVie’s oncology growth opportunity. Article Title
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 from $240 and reiterated an overweight rating, signaling continued analyst confidence in the stock’s outlook. Article Title
• Neutral Sentiment: Media coverage highlighted AbbVie as a high-yield dividend and “quality, low-stress” healthcare stock, which may support investor sentiment but does not change fundamentals. Article Title
• Negative Sentiment: AbbVie lowered its Q2 2026 EPS guidance to $3.57-$3.61 versus the consensus $3.77, suggesting earnings could come in below expectations. Article Title
• Negative Sentiment: The company also cut full-year 2026 EPS guidance to $13.91-$14.11, below the consensus estimate of $14.25, which may pressure the shares despite recent product wins. Article Title

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ABBV shares. Canaccord Genuity Group lifted their price objective on AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Morgan Stanley increased their target price on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Guggenheim restated a “buy” rating and issued a $249.00 price target on shares of AbbVie in a research report on Friday, May 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Finally, Evercore set a $235.00 price objective on shares of AbbVie in a research report on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $256.67.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.